Trust Co Has $2.35 Million Position in Gilead Sciences, Inc. (GILD)

Trust Co boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.9% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 34,525 shares of the biopharmaceutical company’s stock after purchasing an additional 2,215 shares during the period. Trust Co’s holdings in Gilead Sciences were worth $2,345,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Seizert Capital Partners LLC boosted its holdings in Gilead Sciences by 4.6% in the first quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock valued at $42,964,000 after purchasing an additional 27,547 shares during the last quarter. Rockland Trust Co. lifted its holdings in Gilead Sciences by 16.7% during the 1st quarter. Rockland Trust Co. now owns 178,245 shares of the biopharmaceutical company’s stock worth $12,106,000 after buying an additional 25,551 shares during the last quarter. Linscomb & Williams Inc. lifted its holdings in Gilead Sciences by 3.0% during the 1st quarter. Linscomb & Williams Inc. now owns 5,275 shares of the biopharmaceutical company’s stock worth $358,000 after buying an additional 154 shares during the last quarter. Sigma Planning Corp lifted its holdings in Gilead Sciences by 7.7% during the 1st quarter. Sigma Planning Corp now owns 40,168 shares of the biopharmaceutical company’s stock worth $2,728,000 after buying an additional 2,889 shares during the last quarter. Finally, Hollencrest Securities LLC lifted its holdings in Gilead Sciences by 119.8% during the 1st quarter. Hollencrest Securities LLC now owns 7,723 shares of the biopharmaceutical company’s stock worth $525,000 after buying an additional 4,210 shares during the last quarter. 74.05% of the stock is owned by hedge funds and other institutional investors.

In related news, insider John C. Martin sold 73,333 shares of the stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the sale, the insider now owns 3,199,969 shares in the company, valued at approximately $227,197,799. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total transaction of $355,300.00. Following the sale, the executive vice president now owns 102,988 shares in the company, valued at approximately $7,318,327.28. The disclosure for this sale can be found here. Insiders have sold 466,819 shares of company stock worth $36,740,240 over the last ninety days. Insiders own 1.30% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://ledgergazette.com/2017/09/16/trust-co-has-2-35-million-position-in-gilead-sciences-inc-gild.html.

Gilead Sciences, Inc. (NASDAQ GILD) traded up 0.09% during midday trading on Friday, reaching $82.36. The company’s stock had a trading volume of 12,401,948 shares. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27. The firm has a market cap of $107.56 billion, a P/E ratio of 8.95 and a beta of 1.19. The firm has a 50 day moving average price of $77.16 and a 200-day moving average price of $70.20.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. During the same period last year, the firm earned $3.08 earnings per share. The business’s revenue for the quarter was down 8.2% on a year-over-year basis. On average, analysts forecast that Gilead Sciences, Inc. will post $8.75 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be issued a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.53%. Gilead Sciences’s dividend payout ratio is presently 22.58%.

A number of research analysts have commented on the company. Jefferies Group LLC reaffirmed a “hold” rating and set a $80.00 target price on shares of Gilead Sciences in a report on Tuesday, July 11th. BMO Capital Markets reaffirmed an “outperform” rating and set a $82.00 target price (up previously from $72.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Robert W. Baird reaffirmed an “outperform” rating and set a $87.00 target price on shares of Gilead Sciences in a report on Thursday, July 13th. BidaskClub raised Gilead Sciences from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Finally, Leerink Swann reaffirmed a “market perform” rating on shares of Gilead Sciences in a report on Thursday, June 22nd. Eleven analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $83.79.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply